Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

Exclusion Criteria

• •Laser photocoagulation (panretinal or macular) in the study eye within 90 days of day 1
• •Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of day 1
• •Previous treatment with anti-angiogenic drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc.) within 90 days of day 1
• •Active proliferative diabetic retinopathy (PDR) in the study eye
• •Uncontrolled diabetes mellitus
• •Only 1 functional eye even if that eye is otherwise eligible for the study